MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Antidepressants"

  • 2017 International Congress

    The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models.

    T. Collier, L. Lapidus, C. Sortwell, C. Justman, P. Lansbury, K. Paumier (Grand Rapids, MI, USA)

    Objective: Using preclinical models, assess the potential disease-modifying effects of nortriptyline (NOR) as a treatment in early Parkinson’s disease (PD). Background: PD and other synucleinopathies…
  • 2017 International Congress

    The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

    I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effect of mirtazapine, a clinically-available anti-depressant, on psychosis and dyskinesia in Parkinson’s disease (PD). Background: Psychosis and dyskinesia cause significant morbidity…
  • 2017 International Congress

    Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

    M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

    Objective: In this study, we examined neuroprotective effects of mirtazapine and involvement of astrocytes in the effects using primary cultured cells and parkinsonian mice. Background:…
  • 2017 International Congress

    Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression

    E. Dalle, D. William, M. Musa (Durban, South Africa)

    Objective: The objective of this study was to investigate how fluvoxamine maleate treatment regulates depressive-like symptoms, motor impairments and the expressions of IL-1beta, IL-6, IL-10…
  • 2017 International Congress

    Tardive syndromes induced by coadministration of tramadol and sertralin

    H. Sarac, N. Bozina, N. Henigsberg, L. Bagaric-Krakan (Zagreb, Croatia)

    Objective: To illustrate the possible association of tardive syndromes (TS) and coadministration of tramadol and sertraline in three patients. Background: TS is delayed onset of…
  • 2016 International Congress

    Impaired hippocampal neurogenesis associates with serotonergic axonal degeneration in transgenic rat and mouse models of Parkinson’s disease

    Z. Kohl, J. Deußer, D. Amato, C.P. Müller, O. Riess, E. Masliah, S. Nuber, J. Winkler (Erlangen, Germany)

    Objective: To evaluate the impact of α-synuclein accumulation on the hippocampal serotonergic system and hippocampal plasticity in two different α-synuclein expressing rodent models. Background: Parkinson's…
  • 2016 International Congress

    The effects of fluvoxamine maleate in a post-natal stress rat model of neurodegeneration

    E. Dalle, W. Daniels, M. Mabandla (Durban, South Africa)

    Objective: In this study, we investigated whether treatment of anxiety-like symptoms with Fluvoxamine maleate alleviates the neurotoxic effects of 6-OHDA in a Parkinsonian rat model.…
  • 2016 International Congress

    Effects of antidepressants on gait parameters in Parkinson’s disease

    D. Martinez-Ramirez, J.C. Giugni, W. Deeb, M.S. Okun, C.J. Hass (Gainesville, FL, USA)

    Objective: To compare GAITRite parameters between PD patients on antidepressants with patients who were not on any psychotropic. Background: PD patients have an increased risk…
  • 2016 International Congress

    Prevalence of depression in Parkinson’s disease patients

    A.M. Weldehana (Addis Ababa, Ethiopia)

    Objective: The objective of this study was to determine the prevalence of depression in PD patients taking into account the different settings and different diagnostic…
  • 2016 International Congress

    Neuroprotective and antidepressant-like effects of the endogenous amines from tetrahydroisoquinoline group TIQ and 1MeTIQ in the animal model of depressive disorder: Behavioral and neurochemical studies in the rat

    L.R. Antkiewicz-Michaluk (Krakow, Poland)

    Objective: For the purpose of estimation neuroprotective and antidepressant-like effects of the endogenous amines 1,2,3,4-tetrahydroisoquinoline (TIQ) and its close methyl derivative, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) in the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley